Vaxart, Inc. Files 8-K Report
Ticker: VXRT · Form: 8-K · Filed: Aug 15, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, regulatory
Related Tickers: VXRT
TL;DR
Vaxart filed an 8-K on Aug 14, 2025, covering Reg FD and financials. Nothing major disclosed yet.
AI Summary
On August 14, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. Vaxart, Inc. is a biotechnology company focused on developing oral vaccines, previously known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Why It Matters
This 8-K filing provides updates on Vaxart's regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current status and compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by Vaxart, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 14, 2025.
What are some of Vaxart, Inc.'s former company names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
In which state is Vaxart, Inc. incorporated?
Vaxart, Inc. is incorporated in Delaware.
What is Vaxart, Inc.'s business address?
Vaxart, Inc.'s business address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-08-15 13:25:53
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value VXRT * Indicate by check
Filing Documents
- vxrt20250814_8k.htm (8-K) — 28KB
- ex_853830.htm (EX-99.1) — 8KB
- 0001437749-25-027110.txt ( ) — 166KB
- vxrt-20250814.xsd (EX-101.SCH) — 3KB
- vxrt-20250814_def.xml (EX-101.DEF) — 11KB
- vxrt-20250814_lab.xml (EX-101.LAB) — 15KB
- vxrt-20250814_pre.xml (EX-101.PRE) — 11KB
- vxrt20250814_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On August 14, 2025, Vaxart, Inc. (the "Company") issued a press release, announcing that members of the senior management team of the Company will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025, at 4:30 p.m. ET. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated August 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2025 VAXART, INC. /s/ Steven Lo Steven Lo President and Chief Executive Officer